Rhythm Pharmaceuticals Inc.
RYTM
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.05B
Close$
$-23.81
128.1% downside
Current Fair Value
128.1% downsideOvervalued by 128.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.05 Billion |
|---|---|
| Enterprise Value | $6.22 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.11 |
| Beta | 1.94 |
| Outstanding Shares | 67,974,193 |
Return
| Return on Equity | -169.28% |
|---|---|
| Return on Assets | -47.04% |
| Return on Invested Capital | -54.28% |
Valuation & Multiples
| P/E Ratio | -29.62 |
|---|---|
| PEG | -238.75 |
| Price to Sales | 28.24 |
| Price to Book Ratio | 84.71 |
| Enterprise Value to Revenue | 28.63 |
| Enterprise Value to EBIT | -33.78 |
| Enterprise Value to Net Income | -30 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 1.85 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 6, 2026
EPS Estimate
$-0.84
Average shareholder expectationRevenue Estimate
$55.62 M
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$-0.84
Average shareholder expectationRevenue Estimate
$67.53 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1332▼ 59.72% |
|---|---|
| Total Calls | 159,900▼ 58.83% |
| Total Puts | 21,300▼ 92.49% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 110.01%▼ 3.27% |
|---|---|
| Total Invested | $6.42B▼ 17.70% |
| Investors Holding | 290▲ 6.00% |
ESG Score
No data
About Rhythm Pharmaceuticals Inc.
90 employees
CEO: Hunter Smith Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for patients living with rare genetic diseases of obesity. Early-onset severe obesity may result from genetic variants within the mel...